Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia

Long-term remission of T-cell large granular lymphocyte leukemia associated with rheumatoid arthritis after rituximab therapy

“…7 Refractory disease may respond to cyclosporine, cyclophosphamide, 4 or alemtuzumab. 8,9 Complete remissions are rare. Rituximab is a monoclonal anti-CD20 antibody approved for B-cell non-Hodgkin lymphoma 10 and RA.…”

How I treat LGL leukemia

“…The overall response rate on 26 patients is reported at more than 60%. 12,13,69,75,[83][84][85][86][87][88] However, toxicity limits use of this drug in an indolent disease. Furthermore, CD52 has significantly lower expression in leukemic LGL compared with CD8 ϩ normal T cells, and this could explain therapeutic failure in some patients.…”

T-cell large granular lymphocytic (T-LGL) leukemia: a single institution experience

“…Because of the rarity of T-LGL leukemia, very few prospective clinical trials have been reported, and current treatment strategies are based on anecdotal case reports and small retrospective studies. In previous reports, treatment with immunomodulation, corticosteroids, low-dose methotrexate, cyclophosphamide, and cyclosporine A with or without purine analogues are all described [2,[9][10][11][12][13][14][15][16][17][18][19][20][21][22].…”